Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > Cancer Res Treat > Volume 33(3); 2001 > Article
Original Article
A Phase II Trial of UFT-E and Oral Leucovorin in Advanced Colorectal Cancer
Won Sup Lee, Keun Seok Lee, Ki Hyun Kim, Baek Yeol Ryoo, Won Seog Kim, Won Ki Kang, Yoon Koo Kang, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim
Cancer Research and Treatment 2001;33(3): 225-228.
DOI: https://doi.org/10.4143/crt.2001.33.3.225
Published online: June 30, 2001
1Department of Internal Medicine and Clinical ResearchInstitute, Seoul National University College of Medicine.
2Division of Hematology-Oncology, Department of InternalMedicine, Samsung Medical Center, Sungkyunkwan UniversitySchool of Medicine.
3Division of Hematology-Oncology, Department of InternalMedicine, Korea Cancer Center Hospital, Seoul, Korea.
  • 4,116 Views
  • 21 Download
  • 0 Crossref
  • 0 Scopus
prev next

PURPOSE
To determine the efficacy and toxicity of UFT-E plus oral calcium leucovorin in the treatment of patients with advanced colorectal cancer.
MATERIALS AND METHODS
Forty-three patients with advanced, bidimensionally measurable colorectal adenocarcinoma were enrolled in the trial. No patients had received prior palliative chemotherapy. The patients that had received previous adjuvant chemotherapy were enrolled when more than 6 months had elapsed after the completion of adjuvant therapy. Patients were treated with 300 mg/m2/day of UFT-E (tegafur-based) plus 90 mg/day of leucovorin administered orally in three divided daily doses, every 8 hours for 28 days followed by a 7-day rest period. Response was evaluated after two or three courses of therapy.
RESULTS
Thirty-six of forty-three patients were evaluable for response; seven dropped out due to infection, toxicity and patients' refusal. Ten patients had partial responses and one patient complete response (response rate, 31%; 95% confidence interval, 16~46%). The median response duration for the UFT-E plus leucovorin regimen was 28 weeks. Grade III toxicity was seen in one case, with diarrhea.
CONCLUSION
This oral regimen proved effective and well tolerated. This schema also avoided inconveniences, such as hospitalization and the use of infusion pumps, which are associated with 5-FU infusion regimens. The regimen used showed minimal toxicity, especially in the upper digestive tract, with good patient compliance.

  • Cite
    CITE
    export Copy Download
    Close
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    A Phase II Trial of UFT-E and Oral Leucovorin in Advanced Colorectal Cancer
    Cancer Res Treat. 2001;33(3):225-228.   Published online June 30, 2001
    Close

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP